News

VIPC’s Robert Stolle Announces Plans to Step Down From His Role as President and CEO

As CEO, Bob Stolle led Virginia’s consolidation of several innovation and entrepreneurship programs into the newly established VIPC. This consolidation expanded and coordinated programs that provide support for Virginia’s entrepreneurs, tech startups, research commercialization, regional ecosystems, and new industry sectors such as Advanced Air Mobility and Smart Communities.

“Having the privilege of leading VIPC over the last three years has been the most rewarding experience of my professional career” Stolle said. “VIPC has a staff of exceptionally talented and experienced professionals. I’m very proud of where we are as a team, but I believe this is a good time to pass the baton to the next generation of leadership for innovation in Virginia”.

“The Commonwealth has benefited greatly and will continue to benefit for years to come from Bob’s many years of investing his considerable talents, time, and exemplary service,” said Caren Merrick, Secretary of Commerce and Trade and Vice Chair of VIPC.

“Under Bob’s leadership, VIPC has forged a series of integrated programs to help entrepreneurs bring their technologies to commercialization, whether the technology originates in one of Virginia’s academic institutions or in the private sector. As an entrepreneur myself, I know that these programs make a real difference in the success of our emerging and growing tech enterprise,” said Barbara D. Boyan, PhD, Chair of the VIPC Board of Directors and Executive Director of the Institute for Engineering and Medicine at Virginia Commonwealth University.

Joseph Benevento, Virginia Deputy Secretary of Commerce & Trade, will assume the role of Interim CEO beginning in September, while the VIPC Board recruits a permanent CEO. Bob Stolle will stay on in an advisory role to assist in the transition until at least the end of October.

“I’m very grateful to the VIPC Board of Directors and to the Youngkin Administration for their trust, support, and for the opportunity to serve the Commonwealth of Virginia” Stolle said.

Learn more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near